Imatinib-Induced Clinical Response in ETV6::ACSL6 Myeloid Neoplasm with Eosinophilic Pneumonitis: A Case Report

Fieke W. Hoff; Sharon Germans; Olga K. Weinberg; Robert H. Collins Jr.; Rolando García; Weina Chen; Miguel D. Cantu; Mingyi Chen; Prasad Koduru; Jeffrey SoRelle; Yazan F. Madanat; Stephen S. Chung

doi:10.12659/AJCR.946517

09 April 2025 : Case report USA

Imatinib-Induced Clinical Response in ETV6::ACSL6 Myeloid Neoplasm with Eosinophilic Pneumonitis: A Case Report

Unusual or unexpected effect of treatment

Fieke W. Hoff^12ADEF*, Sharon Germans^3BD, Olga K. Weinberg^3BD, Robert H. Collins Jr.^12BD, Rolando García

^3BD, Weina Chen^3BD, Miguel D. Cantu

^3BD, Mingyi Chen

^3BD, Prasad Koduru

^3BD, Jeffrey SoRelle^3BD, Yazan F. Madanat^12ADE, Stephen S. Chung^124ADEG

DOI: 10.12659/AJCR.946517

Am J Case Rep 2025; 26:e946517

Authors information Article notes Copyright and License information

Introduction Case Report Discussion Conclusions References:

Related articles Order reprints Share article Share by email

View HTML version

Figure 3. Graphical visualization of the absolute eosinophil count. Day 0 represent the first day of his hospital admission. High-dose steroids were started at admission and slowly tapered down. On Day 19, imatinib 400 mg daily was given as indicated by the pink bar. The normal absolute eosinophil count (<0.7×109/L) is indicated by the horizontal dashed line in black.

Back to the Article

Imatinib-Induced Clinical Response in ETV6::ACSL6 Myeloid Neoplasm with Eosinophilic Pneumonitis: A Case Report

Your Privacy